What we do

Image
Medical illustrations showing the work of the BMPK Shared Resource

The Bioanalytics, Metabolomics & Pharmacokinetics (BMPK) Shared Resource provides highly sensitive measurements for an extensive array of chemotherapeutic agents and metabolites to support basic research and preclinical/clinical drug development at Roswell Park Comprehensive Cancer Center, in addition to other cancer centers, academic institutions, and industry.

Investigators are encouraged to consult with BMPK as early as possible during the planning phases of their project or grant development. By starting discussions early, BMPK can advise on proper sample collection and handling and provide dosing recommendations for optimal therapeutic outcomes. 

Example categories of drug/metabolite and other small molecule assays using LC-MS/MS for detection:

  • Hormones: Testosterone, dihydrotestosterone, androstenedione, dehydroepiandrosterone (DHEA), and androsterone, and estrone and estradiol
  • Antimetabolites: Gemcitabine and dFdU, capecitabine, and 5-fluorouracil
  • Taxanes: Docetaxel and paclitaxel
  • Topoisomerase Agents: Irinotecan (CPT-11), SN-38, SN-38G
  • Targeted Agents: Tivozanib, enzalutamide and N-desmethylenzalutamide, sorafenib and sorafenib-N-oxide, carfilzomib, sunitinib, dabrafenib, abemaciclib and abemaciclib M2
  • Others: lignans (enterodiol and enterolactone) and eicosanoids

For a complete listing and additional specifications, refer to the table below.

Tools and equipment

Piece of science equipment in the BMPK lab

BMPK instrumentation

  • Applied Biosystems 5500 QTrap triple quadrupole (ESI/APCI-LC/MS/MS)
  • Applied Biosystems 5500 triple quadrupole (ESI/APCI-LC/MS/MS)
  • Thermo Scientific TSQ Vantage triple quadrupole (ESI/APCI-LC/MS/MS)
  • Applied Biosystems API3000 triple quadrupole (ESI LC/MS/MS)
  • Agilent 6545B LC/Q-TOF MS system
  • Tomtec Quadra 4 robotic handling system
Image
Scientist looking at data on computer screens

BMPK modeling software

  • Phoenix WinNonlin: Non-compartmental and compartmental modeling
  • NONMEM: Nonlinear mixed effect modeling software for population analysis to determine sources of variability in the PK and PD of drugs
  • ADAPT 5 and S-ADAPT: individual compartmental PK and PK/PD modeling
  • SAS 9.3: used to manage and clean databases, and create graphics and tables
Analyte(s) Lower Limit of Quantitation
(LLOQ)
Calibration Range Methodology Status Matrices
Androgens (5)
Androstenedione
Testosterone
Dihydrotestosterone Dehydroepiandrosterone
Androsterone
6.25 pg/mL
6.25 pg/mL
12.5 pg/mL
200 pg/mL
200 pg/mL
0.00625 - 3.75 ng/mL
0.00625 - 3.75 ng/mL
0.0125 - 7.50 ng/mL
0.200 - 7.50 ng/mL
0.200 - 7.50 ng/mL
LC-MS/MS Validated Mouse Serum
Human Heparinized Plasma
Human Serum

Biocrates (630 Metabolites)

Variable Variable LC-MS/MS Kit-Based Assay Variable
Calcitriol 10.0 ng/mL 10.0 - 1,000 ng/mL LC-MS/MS Validated Drug Formulation
Carfilzomib 0.400 ng/mL 0.400 - 1,000 ng/mL LC-MS/MS Validated Human Heparinized Plasma
Ceritinib 1.00 ng/mL 1.00 - 500 ng/mL LC-MS/MS Validated Human Plasma
CFAK-C4 2.50 pg/mL 2.50 - 2,500 pg/mL LC-MS/MS Qualified Dog Heparinized Plasma
Cytarabine 1.00 ng/mL 1.00 - 1,000 ng/mL LC-MS/MS Qualified Human Plasma
Docetaxel 0.200 ng/mL 0.200 - 400 ng/mL LC-MS/MS Validated Human Plasma
Docetaxel
Docetaxel M1
Docetaxel M2
Docetaxel M3
Docetaxel M4
5.00 ng/mL
5.00 ng/mL
5.00 ng/mL
5.00 ng/mL
7.50 ng/mL
5.00 - 1,000 ng/mL
5.00 - 1,000 ng/mL
5.00 - 1,000 ng/mL
5.00 - 1,000 ng/mL
7.50 - 1,500 ng/mL
LC-MS/MS Qualified Mouse Plasma
Rat Plasma
Dog Plasma
Human Plasma
Dovitinib 2.00 ng/mL 2.00 - 1,000 ng/mL LC-MS/MS Qualified Human Heparinized Plasma
Eicosanoids (7)
Prostaglandin D2
Prostaglandin E2
13-Hydroxyoctadecadienoic acid
5-Hydroxyeicosatetraenoic acid
12-Hydroxyeicosatetraenoic acid
15-Hydroxyeicosatetraenoic acid
Arachidonic Acid
1.00 ng/mL 1.00 - 400 ng/mL LC-MS/MS Qualified Mouse Xenografts
Enterodiol
Enterolactone
0.500 ng/mL
0.500 ng/mL
0.500 - 150 ng/mL
0.500 - 150 ng/mL
LC-MS/MS Validated Human Serum
Entinostat 0.500 ng/mL 0.500 - 250 ng/mL LC-MS/MS Qualified Human Plasma
Enzalutamide
N-Desmethyl Enzalutamide
10.0 ng/mL
10.0 ng/mL
10.0 - 20,000 ng/mL
10.0 - 20,000 ng/mL
LC-MS/MS Validated Human EDTA Plasma
Enzalutamide
N-Desmethyl Enzalutamide
10.0 ng/mL
10.0 ng/mL
10.0 - 20,000 ng/mL
10.0 - 20,000 ng/mL
LC-MS/MS Qualified Woodchuck EDTA Plasma
Epacadostat 5.00 ng/mL 5.00 - 1,000 ng/mL LC-MS/MS Validated Human EDTA Plasma
Estrone and
17ß-Estradiol
2.00 pg/mL
1.00 pg/mL
2.00 - 250 pg/mL
1.00 - 250 pg/mL
LC-MS/MS Validated Human Heparinized Plasma
Human Serum
Gemcitabine
dFdU
1.00 ng/mL
5.00 ng/mL
1.00 - 2,000 ng/mL
5.00 - 10,000 ng/mL
LC-MS/MS Validated Human Plasma
Gemcitabine
dFdU
Capecitabine
5-Fluorouracil
5-DFCR
5-DFUR
1.00 ng/mL
1.00 ng/mL
1.00 ng/mL
5.00 ng/mL
5.00 ng/mL
5.00 ng/mL
1.00 - 1,000 ng/mL
1.00 - 1,000 ng/mL
1.00 - 1,000 ng/mL
5.00 - 1,000 ng/mL
5.00 - 1,000 ng/mL
5.00 - 1,000 ng/mL
LC-MS/MS Qualified Human Plasma
JP-11646 1.00 ng/mL 1.00 - 500 ng/mL LC-MS/MS Validated Mouse Plasma
Rat Plasma
Dog Plasma
Mannitol
Lactulose
3-MGP
0.980 µg/mL
0.980 µg/mL
2.93 µg/mL
0.980 - 62.5 µg/mL
0.980 - 62.5 µg/mL
2.93 - 62.5 µg/mL
LC-MS/MS Qualified Human Plasma
Nicotine
Cotinine
Hydroxy Cotinine
Cotinine Glucuronide
Anatabine
Atabasine
1.00 ng/mL
1.00 ng/mL
1.00 ng/mL
10.0 ng/mL
1.00 ng/mL
1.00 ng/mL
1.00 - 100 ng/mL
1.00 - 100 ng/mL
1.00 - 100 ng/mL
10.0 - 500 ng/mL
1.00 - 100 ng/mL
1.00 - 100 ng/mL
LC-MS/MS Qualified Human Urine
Nintedanib 0.500 ng/mL 0.500 - 250 ng/mL LC-MS/MS Validated Human EDTA Plasma
Paclitaxel and
6α-Hydroxy Paclitaxel
2.00 ng/mL
2.00 ng/mL
2.00 - 1,000 ng/mL
2.00 - 1,000 ng/mL
LC-MS/MS Validated Human Plasma
Pemetrexed 5.00 ng/mL 5.00 - 2,000 ng/mL LC-MS/MS Qualified Human Plasma
Rapamycin 1.25 ng/mL 1.25 - 100 ng/mL LC-MS/MS Validated Human Plasma
Sorafenib
Sorafenib N-oxide
50.0 ng/mL
12.5 ng/mL
50.0 - 10,000 ng/mL
12.5 - 2,500 ng/mL
LC-MS/MS Validated Human Plasma
Sorafenib
Sorafenib N-oxide
50.0 ng/mL
12.5 ng/mL
50.0 - 10,000 ng/mL
12.5 - 2,500 ng/mL
LC-MS/MS Qualified Woodchuck Plasma
(Z)-Tamoxifen
(Z)-N-Desmethyltamoxifen
(Z)-4-Endoxifen
(Z)-4-Hydoxytamoxifen
1.00 ng/mL
1.00 ng/mL
0.500 ng/mL
0.250 ng/mL
1.00 - 400 ng/mL
1.00 - 400 ng/mL
0.500 - 200 ng/mL
0.250 - 100 ng/mL
LC-MS/MS Validated Human Plasma
Human Breast Tissue
Tivozanib 0.500 ng/mL 0.500 - 150 ng/mL LC-MS/MS Validated Human EDTA Plasma
Tryptophan and Kynurenine 40.0 ng/mL
10.0 ng/mL
40.0 - 20,000 ng/mL
10.0 - 5,000 ng/mL
LC-MS/MS Validated Human Plasma

Fees

Collaborative interaction is essential to achieve optimal experimental design and outcomes. As a client of BMPK, we will arrange a one-on-one consultation with you to review your experimental design, method development needs, sample analysis strategy, and results interpretation in order to best meet your study aims and objectives. Over the course of the study, we will work closely with you to ensure that you receive the most pertinent and reliable outcomes possible. As a result, pricing varies with experimental design, turnaround time, the number of analytes as well as the number of samples.

Investigators interested in the use of the BMPK Shared Resource should contact Joshua Prey to discuss scheduling, shared resource procedures and pricing.

Contact us
Image
Roswell Park Comprehensive Cancer Center

Location and hours

Roswell Park Comprehensive Cancer Center
Bioanalytics, Metabolomics & Pharmacokinetics Shared Resource
Center for Genetics and Pharmacology, Room L1-140
Elm and Carlton Streets
Buffalo, New York 14263

Monday - Friday, 8 a.m. - 5 p.m.

BMPK is partially funded by NCI P30CA16056. Authors should cite the core grant in the acknowledgment section of the publication if data that was generated by BMPK is used in the publication. Two copies of the publication, acknowledging the core grant, should be submitted to the facility at Elm and Carlton Streets, Buffalo NY, 14263.

For BMPK facility data, please click here.

  • Fountzilas C, Adjei A, Opyrchal M, Evans R, Ghasemi M, Attwood K, Groman A, Bshara W, Goey AKL, Wilton J, Ma WW, Iyer R. A phase 1 study of the ALK inhibitor ceritinib in combination with gemcitabine-based chemotherapy in patients with advanced solid tumors. Int J Cancer. 2021 Dec 15;149(12):2063-2074. doi: 10.1002/ijc.33754. PMID: 34319586.
  • Harding JJ, Kelley RK, Tan B, Capanu M, Do GK, Shia J, Chou JF, Ferrer CS, Boussayoud C, Muenkel K, Yarmohammadi H, El Dika I, Khalil DN, Ruiz C, Rodriguez-Lee M, Kuhn P, Wilton J, Iyer R, Abou-Alfa GK. Phase Ib Study of Enzalutamide with or Without Sorafenib in Patients with Advanced Hepatocellular Carcinoma. Oncologist. 2020 Dec;25(12):e1825-e1836. doi: 10.1634/theoncologist.2020-0521. PMID: 32548867.
  • Iyer RV, Konda B, Fountzilas C, Mukherjee S, Owen D, Attwood K, Wang C, Maguire O, Minderman H, Suffren SA, Hicks K, Wilton J, Bies R, Casucci D, Reidy-Lagunes D, Shah M. Multicenter phase 2 trial of nintedanib in advanced nonpancreatic neuroendocrine tumors. Cancer. 2020 Aug 15;126(16):3689-3697. doi: 10.1002/cncr.32994. PMID: 32525561.
  • Fountzilas C, Gupta M, Lee S, Krishnamurthi S, Estfan B, Wang K, Attwood K, Wilton J, Bies R, Bshara W, Iyer R. A multicentre phase 1b/2 study of tivozanib in patients with advanced inoperable hepatocellular carcinoma. Br J Cancer. 2020 Mar;122(7):963-970. doi: 10.1038/s41416-020-0737-6. PMCID: PMC7109127.
  • Affronti HC, Rowsam A, Pellerite AJ, Rosario S, Long M, Jacobi J, Bianchi-Smiraglia A, Boerlin CS, Gillard B, Karasik E, Foster B, Moser M, Wilton J, Attwood K, Nikiforov MA, Azabdaftari G, Pili R, Phillips JG, Casero RA Jr, Smiraglia D. Pharmacological polyamine catabolism upregulation with methionine salvage pathway inhibition as an effective prostate cancer therapy. Nat Commun. 2020 Jan 7;11(1):52. doi 10.1038/s41467-019-13950-4. PMCID: PMC6946658.
  • Kamoun WS, Kirpotin DB, Huang ZR, Tipparaju SK, Noble CO, Hayes ME, Luus L, Koshkaryev A, Kim J, Olivier K, Kornaga T, Oyama S, Askoxylakis V, Pien C, Kuesters G, Dumont N, Lugovskoy AA, Schihl SA, Wilton JH, Geddie ML, Suchy J, Grabow S, Kohli N, Reynolds CP, Blaydes R, Zhou Y, Sawyer AJ, Marks JD, Drummond DC. Antitumour activity and tolerability of an EphA2-targeted nanotherapeutic in multiple mouse models. Nat Biomed Eng. 2019 Apr;3(4):264-280. doi: 10.1038/s41551-019-0385-4. PMID: 30952988.
  • Ma WW, Xie H, Fetterly G, Pitzonka L, Whitworth A, LeVea C, Wilton J, Mantione K, Schihl S, Dy GK, Boland P, Iyer R, Tan W, Brady W, Straubinger RM, Adjei AA. A Phase Ib Study of the FGFR/VEGFR Inhibitor Dovitinib With Gemcitabine and Capecitabine in Advanced Solid Tumor and Pancreatic Cancer Patients. Am J Clin Oncol. 2019 Feb;42(2):184-189. doi: 10.1097/COC.0000000000000492 PMCID: PMC6345595
  • Cook SF, Fiandalo MV, Watt DS, Wu Y, Mohler JL, Bies RR. Mathematical modeling of intracrine androgen metabolism in prostate cancer: Methodological aspects. Prostate. 2018 Jun 25. doi: 10.1002/pros.23665. PMID: 29938815
  • Hess TA, Drinkhouse ME, Prey JD, Miller JM, Fettig AA, Carberry CA, Brenn SH, Bailey DB. Analysis of platinum content in biodegradable carboplatin-impregnated beads and retrospective assessment of tolerability for intralesional use of the beads in dogs following excision of subcutaneous sarcomas: 29 cases (2011-2014). J Am Vet Med Assoc. 2018 Feb 15;252(4):448-456. doi: 10.2460/javma.252.4.448 PMID: 29393745
  • Fiandalo MV, Wilton JH, Mantione KM, Wrzosek C, Attwood KM, Wu Y, Mohler JL. Serum-free complete medium, an alternative medium to mimic androgen deprivation in human prostate cancer cell line models. Prostate. 2018 Feb;78(3):213-221. doi: 10.1002/pros.23459. Epub 2017 Dec 1 PMCID: PMC5768451
  • Fiandalo MV, Stocking JJ, Pop EA, Wilton JH, Mantione KM, Li Y, Attwood KM, Azabdaftari G, Wu Y, Watt DS, Wilson EM, Mohler JL. Inhibition of dihydrotestosterone synthesis in prostate cancer by combined frontdoor and backdoor pathway blockade. Oncotarget. 2018 Jan 10;9(13):11227-11242. doi: 10.18632/oncotarget.24107. eCollection 2018 Feb 16 PMCID: PMC5834294
  • Vicky C. Chang, Michelle Cotterchio, Beatrice A. Boucher, David J. A. Jenkins, Lucia Mirea, Susan E. McCann & Lilian U. Thompson (2018) Effect of Dietary Flaxseed Intake on Circulating Sex Hormone Levels among Postmenopausal Women: A Randomized Controlled Intervention Trial, Nutrition and Cancer, DOI: 10.1080/01635581.2018.1516789